Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2017. Revenue for the quarter was $601.3 million, a 13...
ResMed (NYSE: RMD, ASX: RMD) today introduced Mobi, its first ResMed-branded portable oxygen concentrator (POC). Mobi offers an industry-leading...
ResMed (NYSE: RMD) today announced it will report its second quarter of fiscal year 2018 results on Monday, January 22, 2018, after the New York...
ResMed (NYSE: RMD, ASX: RMD) today issued the following statement from David Pendarvis, the company's global general counsel and chief administrative ...
ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2017. Revenue for the quarter was $523.7 million, a 13...
ResMed (NYSE: RMD) ha anunciado hoy el lanzamiento europeo de su mascarilla nasal AirFit N20 Classic para el tratamiento con presión positiva de las...
ResMed (NYSE : RMD) a annoncé aujourd'hui la sortie européenne de son masque nasal AirFit N20 Classic pour le traitement par ventilation à pression...
ResMed (NYSE: RMD) gab heute die Markteinführung in Europa der AirFit N20 Classic Nasenmaske für die Behandlung mit positivem Atemdruck (PAP) bekannt ...
ResMed (NYSE: RMD) (ASX: RMD), the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory...
ResMed (NYSE: RMD) (ASX: RMD) the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory...
ResMed (NYSE: RMD) today announced it will report its first quarter of fiscal year 2018 results on Thursday, October 26, 2017, after the New York...
ResMed Inc. (NYSE: RMD) today announced results for its quarter ended June 30, 2017. Revenue for the quarter was $556.7 million, a 7 percent increase ...
ResMed (NYSE: RMD) today announced it will report its fourth quarter of fiscal year 2017 results on Tuesday, August 1, 2017, after the New York Stock ...
According to a new ResMed-sponsored (NYSE:RMD) study, people with treatment-emergent central sleep apnea (CSA) have a significantly greater risk of...
People suffering from chronic obstructive pulmonary disease (COPD) – the third leading cause of death in the United States – may see their lives...
ResMed (NYSE: RMD) today announced its AirTouch F20 full face mask with UltraSoft memory foam mask cushion, a breakthrough in the treatment of sleep...
ResMed Inc. (NYSE: RMD) today announced results for its quarter ended March 31, 2017. Revenue for the quarter was $514.2 million, a 13 percent...
ResMed (NYSE: RMD) today unveiled its AirMini™, the world's smallest CPAP machine – a game-changer for people with sleep apnea. Experience the...
ResMed Inc. (NYSE: RMD) today announced it will report its third quarter of fiscal year 2017 results on Thursday, April 27, 2017 after the New York...
ResMed (NYSE:RMD) today announced publication of a study in the Journal of the American College of Cardiology (JACC), which investigated whether...
ResMed's global lead in remote patient monitoring kept growing in 2016, even as the industry itself continued to expand, according to the annual...
ResMed Inc. (NYSE: RMD) today announced results for its quarter ended December 31, 2016. Revenue for the quarter was $530.4 million, a 17 percent...
ResMed (NYSE:RMD), BMC (Beijing, China) and 3B Medical (Winter Haven, Florida) today announced they have agreed on a global settlement of all...
ResMed (NYSE:RMD) today announced new European research from Price Waterhouse Coopers (PwC), revealing that patients with sleep apnea who use...
ResMed (NYSE:RMD) announced today at the 35th annual J.P. Morgan Healthcare Conference that the U.S. Food and Drug Administration has cleared...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.